Biotricity Inc. (BTCY)
OTC PINK OTC PINK Primary 
Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals
REDWOOD CITY, CA / ACCESSWIRE / September 19, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting edge remote monitoring and diagnostic solutions, announces the launch of a new cardiac monitoring pilot program with a top hospital system. With 90% of U.S. adults at risk of developing cardiovascular disease and a projected shortage of up to 124K physicians in the next 12 years, the demand for Biotricity's innovative cardiac monitoring solutions has never been more urgent.
Biotricity Reports Continued Margin Improvement and Reduced Losses in its First Quarter Fiscal Year 2025
The Company shows continued progress towards cash-flow break even and profitability Recurring Technology Fee (SaaS) revenue - over 94% of total revenue with a 76% gross margin, which rose over 400 basis points and is expected to continue to trend higher Gross margins improved significantly to 73.8 from 63.5% in the same period last year, and 59.6% 2 years earlier Reduced SG&A to $3 million, down 16% compared to same period last year Operating loss of $1.1 million, indicated efficiency gains of $1.2 million from the preceding year quarter - a 51.8% improvement Growth in revenue of 6% YOY to $3.2 million EBITDA and Adjusted EBITDA improved by 18.9% and 49.8%, respectively, from the corresponding period in the prior year; Quarter over preceding Quarter, EBITDA improved by $1M, or 36%, whereas Adjusted EBITDA improved by $1.5M or 59%. Comprehensive loss was reported at $6.9 million, due to one-time non-cash items of $3.2 million; removing these would have resulted in a net loss of $3.7 million, consistent with prior year levels of $3.8 million due to interest rate increases that countered the impact of efficiency gains REDWOOD CITY, CA / ACCESSWIRE / August 21, 2024 / Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2025 year ended June 30, 2024.
LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m.
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform. The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters.
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m.
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET).
Biotricity Announces Accelerated Path to EBITDA Positive
REDWOOD CITY, CA / ACCESSWIRE / July 11, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program
REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states. Biotricity's cardiac monitoring solution is the only three-channel connected solution in the world.
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Democratizing cardiac health with convenient, rapid, and reliable results REDWOOD CITY, CA / ACCESSWIRE / June 28, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announced its groundbreaking direct-to-consumer heart health screening service, HeartSecure, is now available for purchase online at HeartSecure. Heart disease remains the leading cause of death worldwide, with someone succumbing to cardiovascular disease (CVD) every 1.5 seconds.
Biotricity, Inc. (BTCY) Q4 2024 Earnings Call Transcript
Biotricity, Inc. (NASDAQ:BTCY ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Donovan - H.C. Wainwright Operator Greetings, and welcome to the Biotricity Fiscal Year 2024 Financial Results and Business Update Call.
Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability
FY24 revenue up 25.2% YOY FY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continue FY24 operating expenses lower by 17.6% YOY Negative EBITDA reduced by $7.2 million - an improvement of 44.6% -- accelerating the Company's path to breakeven and EBITDA positive REDWOOD CITY, CA / ACCESSWIRE / June 27, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "Fiscal 2024 has been a year of massive transformation for Biotricity.
Biotricity to Host Fourth Quarter and Fiscal Year 2024 Financial Results and Business Update Call on June 27
REDWOOD CITY, CA / ACCESSWIRE / June 26, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its fourth quarter and fiscal year 2024 financial results and business update call on Thursday, June 27, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.
